Scientists at The University of Texas at El Paso have found a promising new target in the fight against high-grade serous carcinoma, an aggressive form of ovarian cancer. Less than 50 percent of women ...

SINGAPORE – Has your dog been keeping you up at night with constant whining and scratching of its ears? Or you cannot seem to keep its ears clean no matter how much you wipe them? Your dog could be ...

The FDA granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack) for the treatment of adults with KRAS-mutated, recurrent low-grade serous ovarian ...

(a) Papillary growth pattern with columnar, pseudostratified tumor cells. This morphology can mimic HPV-associated usual-type endocervical adenocarcinoma. (b) Solid growth composed of round to ovoid ...

Opportunistic salpingectomy (OS) is feasible but not performed in almost a quarter of patients later diagnosed with high-grade serous carcinoma (HGSC), and about 40% of patients with a first-degree ...

Dr. Rui Han Liu (Otolaryngology): A 34-year-old man was admitted to this hospital because of pain in the left ear with hearing loss, facial droop on the left side, and a nasopharyngeal mass that was ...

ANN ARBOR, Michigan — A new study explains the genetic underpinnings of a rare and aggressive form of ovarian cancer – and offers a potential pathway for new treatments. High-grade serous carcinoma, ...

The combination of avutometinib and defactinib is the first FDA-approved treatment for KRAS-mutated recurrent LGSOC. Approval was based on the phase 2 RAMP-201 trial, showing a 44% overall response ...

A rare type of ovarian cancer that grows slowly and responds poorly to chemotherapy now has its first FDA-approved treatment, a combination drug developed by Verastem Oncology to address a pathway ...

The FDA approved Avmapki Fakzynja Co-pack for KRAS-mutated, recurrent, low-grade serous ovarian cancer after prior systemic therapy. The RAMP-201 trial showed a 44% response rate, with response ...